Who
Christopher Haqq
Officer
Company insider
Files Form 4 as: Officer, Elicio Therapeutics; Other, Surrozen; EVP, R&D & Chief Scientific Of, Atara Biotherapeutics.
In numbers
- Trades disclosed
- 103
- Buys
- 0
- Sells
- 35
- Bought
- $0
- Sold
- $7.6M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 15 Oct 2014
- Last trade
- 16 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 17 Jul 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,643 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,643 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELTX Elicio TherapeuticsBiotechnology | SEC FORM 4 Code A | —25,400 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,900 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,900 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELTX Elicio TherapeuticsBiotechnology | SEC FORM 4 Code A | —25,400 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 30 Sep 2024filed 2 Oct 2024 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,200 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,200 at $0.00 | filing |
| 11 Aug 2021filed 13 Aug 2021 | SRZN SurrozenBiotechnology | SEC FORM 4 Code A | —30,000 | filing |
| 11 Aug 2021filed 13 Aug 2021 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 15 Feb 2019filed 19 Feb 2019 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $31K775 at $39.59 | filing |
| 11 Feb 2019filed 11 Feb 2019 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $539K13,975 at $38.55 | filing |
| 6 Feb 2019filed 8 Feb 2019 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 6 Feb 2019filed 8 Feb 2019 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $102K2,677 at $38.04 | filing |
| 6 Feb 2019filed 8 Feb 2019 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $376K9,698 at $38.78 | filing |
| 6 Feb 2019filed 8 Feb 2019 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $58K1,512 at $38.47 | filing |
| 6 Feb 2019filed 8 Feb 2019 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 15 Nov 2018filed 15 Nov 2018 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $26K775 at $33.81 | filing |
| 26 Sep 2018filed 27 Sep 2018 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $582K13,500 at $43.08 | filing |
News
No headline names them, or the companies they trade most, lately.